Hinge Health (HNGE) Stock Price, News & Analysis

Company Overview

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs. Participants gain access to on-demand exercise regimens, progress tracking via connected sensors and remote clinician support—all designed to address conditions ranging from back and joint pain to post-surgical rehabilitation. The platform also leverages data analytics and outcomes measurement to continually refine its care pathways and demonstrate value to its clients.

Hinge Health has built a leadership team rooted in digital health, physical therapy and behavioral science, led by co-founder and CEO Daniel Perez. Through collaborations with major corporations, insurers and provider networks, the company is expanding its reach across the United States and into select international markets. By simplifying access to high-quality MSK care, Hinge Health seeks to transform how organizations manage one of the most prevalent and costly health challenges globally.

Key Stats

• Today's Range: $48.08 to $55.79
• 50-Day Range: $35.39 to $54.15
• 52-Week Range: $30.08 to $62.18
• Volume: 5.10 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: $4.26 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.40
• Consensus Rating: Moderate Buy

Hinge Health Stock Analysis - MarketRank™

Hinge Health scored higher than 84% of companies evaluated by MarketBeat, and ranked 84th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hinge Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 16 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Hinge Health has a consensus price target of $67.40, representing about 24.5% upside from its current price of $54.15.

Amount of Analyst Coverage

Hinge Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.38%

Earnings Growth

Earnings for Hinge Health are expected to grow by 15.38% in the coming year, from $0.78 to $0.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hinge Health is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hinge Health is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hinge Health has a P/B Ratio of 23.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.02% of the float of Hinge Health has been sold short.

Short Interest Ratio / Days to Cover

Hinge Health has a short interest ratio ("days to cover") of 5.82.

Change versus previous month

Short interest in Hinge Health has recently decreased by 5.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hinge Health does not currently pay a dividend.

Dividend Growth

Hinge Health does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.54

News Sentiment

Hinge Health has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for Hinge Health this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for HNGE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added Hinge Health to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Hinge Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,786,901.00 in company stock.

Percentage Held by Insiders

18.92% of the stock of Hinge Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Hinge Health has minimal institutional ownership at this time.

HNGE Stock Analysis - Frequently Asked Questions

How have HNGE shares performed this year?

Hinge Health's stock was trading at $46.42 at the start of the year. Since then, HNGE stock has increased by 16.6% and is now trading at $54.1460.

How were Hinge Health's earnings last quarter?

Hinge Health Inc. (NYSE:HNGE) issued its quarterly earnings results on Tuesday, May, 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.33. The company's revenue for the quarter was up 47.2% on a year-over-year basis.
Read the conference call transcript.

How will Hinge Health's stock buyback program work?

Hinge Health's board authorized a share buyback program on Wednesday, November 12th 2025, which allows the company to buy back $250,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 7.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

When did Hinge Health IPO?

Hinge Health (HNGE) raised $410 million in an IPO on Thursday, May 22nd 2025. The company issued 13,666,000 shares at a price of $28.00-$32.00 per share.

Who are Hinge Health's major shareholders?

Hinge Health's top institutional shareholders include Emerald Advisers LLC (0.35%), Principal Financial Group Inc. (0.24%), Emerald Mutual Fund Advisers Trust (0.23%) and Kornitzer Capital Management Inc. KS (0.13%). Insiders that own company stock include Bessemer Venture Partners X L, James Pursley, James Budge, Gabriel MI Mecklenburg, Kristina M Leslie, Insight Holdings Group, Llc and Daniel Antonio Perez.
View institutional ownership trends.

How do I buy shares of Hinge Health?

Shares of HNGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Business Services
• Current Symbol: NYSE:HNGE
• Previous Symbol: NYSE:HNGE
• CIK: 1673743
• Web: N/A
• Phone: (415) 689-8429
• Fax: N/A
• Employees: 1,437
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Hinge Health: $67.40
• High Price Target: $95.00
• Low Price Target: $45.00
• Potential Upside/Downside: +24.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$528.26 million
• Net Margins: -78.95%
• Pretax Margin: -89.69%
• Return on Equity: -279.39%
• Return on Assets: -70.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.47
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $587.86 million
• Price / Sales: 7.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.26 per share
• Price / Book: 23.96

Miscellaneous

• Outstanding Shares: 78,760,000
• Free Float: 63,861,000
• Market Cap: $4.26 billion
• Optionable: N/A
• Beta: N/A